Zumutor Biologics: Financial Breakdown
Decoding financial health metrics of Zumutor Biologics
Total Revenue₹13.0 Cr-41%Prev. FY
Total Expenses₹11.1 Cr-42%Prev. FY
Profit After Tax₹1.4 Cr-35%Prev. FY
Total Assets₹52.8 Cr4%Prev. FY
Net Profit Margin10.7%10%Prev. FY
FAQs on Financials of Zumutor Biologics
No. In FY25, Zumutor Biologics reported a net loss of ₹3.9 Cr, so it was not profitable.
Zumutor Biologics's revenue declined 64.3% year-on-year, from ₹13.0 Cr in FY24 to ₹4.6 Cr in FY25.
Zumutor Biologics's estimated EBITDA for FY25 was ₹-3.4 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY25, Zumutor Biologics posted revenue of ₹4.6 Cr (down 64.3% YoY) and a net loss of ₹3.9 Cr. Explore the full financials of Zumutor Biologics here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links